Rigel Pharmaceuticals (RIGL) is on a roll, hitting new 52-week highs and seeing a 243% increase in shares over the past year. Despite positive analyst ratings and projected earnings growth this year, caution is advised as revenue and earnings are expected to decline next year. With a market capitalization of $744 million, RIGL focuses on developing drugs for various diseases. The stock has gained 242.55% in the past year and has a strong buy opinion from Barchart. Analysts are split on RIGL, with price targets ranging from $23-$57, but the stock is currently considered overvalued by Morningstar. It’s important to note the stock’s volatility and use strict risk management strategies.

Read more at Yahoo Finance: This ‘Darling’ Pharma Stock Is Hitting New Highs, But the Momentum Could Run Out Soon